Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

266.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 266.86
Bid (Size) 264.00 (1)
Ask (Size) 268.50 (1)
Prev. Close 266.86
Today's Range 266.86 - 266.86
52wk Range 218.44 - 296.67
Shares Outstanding N/A
Dividend Yield 2.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of... 
Via Benzinga
Exposures Product Safety
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+1.99%
+1.99%
1 Month
+4.02%
+4.02%
3 Month
+18.75%
+18.75%
6 Month
+12.71%
+12.71%
1 Year
+17.63%
+17.63%

More News

Read More
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
Via FinancialNewsMedia
2 Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
Via Benzinga
Amgen Unusual Options Activity
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
Via Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Shares of Neumora Therapeutics Slumped This Week
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Quality Dividend Stocks For A Bear Market
Via Talk Markets
Topics Economy
Exposures Economy
2 Top Dividend Stocks to Buy in September
Via The Motley Fool
How Is The Market Feeling About Amgen?
Via Benzinga
8 Analysts Have This to Say About Amgen
Via Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
Via InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Via Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
Via Benzinga
3 Growth Stocks to Buy in September
Via MarketBeat
Topics Economy
Exposures Economy
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
Via Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
The 3 Most Promising Dow Stocks to Own Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Via The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.